Clinical advancement in the management of mutant isocitrate dehydrogenase (IDH) cancers [0.03%]
异柠檬酸脱氢酶(IDH)突变癌症治疗手段的临床进展
John Bridgewater,Ghazaleh Tabatabai,Teresa Macarulla et al.
John Bridgewater et al.
The use of mutant isocitrate dehydrogenase (mIDH) inhibitors has been investigated and has shown significant improvement in survival outcomes in patients with a range of mIDH cancers, including acute myeloid leukaemia (AML), cholangiocarcin...
Isocitrate dehydrogenase mutations as potential tumour agnostic targets [0.03%]
异柠檬酸脱氢酶突变作为潜在的肿瘤agnostic靶点
Teresa Macarulla,Ghazaleh Tabatabai,Silvia Stacchiotti et al.
Teresa Macarulla et al.
The isocitrate dehydrogenase (IDH) family of proteins comprises three important metabolic enzymes that convert isocitrate to alpha ketoglutarate (α-KG) via oxidative decarboxylation. The IDH enzymes play important roles in epigenetic regul...
Use of [177Lu]Lu-DOTA-TATE in the treatment of gastroenteropancreatic neuroendocrine tumours: Results of a UK cost-effectiveness modelling study [0.03%]
177Lu-DOTA-TATE在胃肠胰神经内分泌肿瘤治疗中的成本效益模型研究结果英国经验
Matthew Glover,Martyn Caplin,Oscar R Leeuwenkamp et al.
Matthew Glover et al.
Aim: To evaluate the cost-effectiveness of [177Lu]Lu-DOTA-TATE versus relevant comparators for the treatment of neuroendocrine tumours located in the gastrointestinal tract (GI-NETs) and the pancreas (P-NETs). ...
Matching-adjusted indirect treatment comparison of [177Lu]Lu-DOTA-TATE, everolimus and sunitinib in advanced, unresectable gastroenteropancreatic neuroendocrine tumours: Relative effectiveness of [177Lu]Lu-DOTA-TATE in gastroenteropancreatic neuroendocrine tumours [0.03%]
[177Lu]Lu-DOTA-TATE与everolimus和sunitinib治疗晚期不可切除的消化道神经内分泌瘤的匹配调整间接比较研究：[177Lu]Lu-DOTA-TATE在消化道神经内分泌肿瘤中的相对有效性
Mohid S Khan,Elaine Stamp,Cormac Sammon et al.
Mohid S Khan et al.
Head-to-head comparisons of the efficacy of treatments for gastroenteropancreatic neuroendocrine tumours (GEP-NETs) have not yet been reported. This study used a series of matching-adjusted indirect comparisons to indirectly compare the eff...
Can the peptide receptor radionuclide therapy [177Lu]Lu-DOTA-TATE provide a net benefit for NET patients? [0.03%]
镥-177-DOTA-TATE肽受体核素治疗可给神经内分泌肿瘤患者带来净获益吗？
Martyn E Caplin
Martyn E Caplin
Marta Gil-Martin,Beatriz Pardo,Maria-Pilar Barretina-Ginesta
Marta Gil-Martin
Aim: The description of rare malignant ovarian tumours and the most suitable treatments. Alternative therapies different from intravenous chemotherapy are also explained. ...
Elena García-Martínez,J Alejandro Pérez-Fidalgo
Elena García-Martínez
Ovarian cancer is the leading cause of death for gynaecological cancer, and new therapies are urgently awaited. Although the presence of tumour-infiltrating lymphocytes has been confirmed to be associated to a better prognosis, immunotherap...
Yolanda García García,Maria Marín Alcalá,Clara Martínez Vila
Yolanda García García
Angiogenesis is a known hallmark in cancer and plays a crucial role in ovarian cancer carcinogenesis and invasion. Anti- angiogenic agents are active in ovarian cancer treatment either as monotherapy or combined with chemotherapy, immunothe...
J Alejandro Perez-Fidalgo
J Alejandro Perez-Fidalgo
Cancer is characterised by uncontrolled proliferation and prolonged cell survival. In some cases, tumour formation is the result from aberrant activity of various cell-cycle regulators leading to chromosome instability or from alteration of...
Maria-Pilar Barretina-Ginesta
Maria-Pilar Barretina-Ginesta
Epithelial ovarian cancer (EOC) is very sensitive to upfront chemotherapy. This condition is attributable to defects in the DNA damage repair system. Agents that damage DNA are the main drugs used for its treatment. Many EOC cells have DNA ...